Tesamorelin
From Infogalactic: the planetary knowledge core
Clinical data | |
---|---|
Trade names | Egrifta |
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a611035 |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Subcutaneous injection |
Pharmacokinetic data | |
Bioavailability | ≤4%[1] |
Metabolism | Proteolysis |
Biological half-life | 26–38 min |
Excretion | Renal/proteolysis |
Identifiers | |
CAS Number | 901758-09-6 |
ATC code | H01AC06 (WHO) |
PubChem | CID: 16137828 |
ChemSpider | 34982925 |
UNII | MQG94M5EEO |
KEGG | D09015 |
Chemical data | |
Formula | C221H366N72O67S |
Molecular mass | 5135.86 g/mol |
|
|
|
Lua error in package.lua at line 80: module 'strict' not found.
Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada.
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.[2]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with reference errors
- Drugs with non-standard legal status
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles containing unverified chemical infoboxes
- Growth hormone secretagogues
- Growth hormone-releasing hormone receptor agonists
- HIV/AIDS
- Hormonal agents
- Peptides
- Recombinant proteins
- Systemic hormonal preparation stubs